Interim pharmacokinetic (PK) and pharmacodynamic (PD) data from the first-in-human study of NUC-3373, a pyrimidine nucleotide analogue, in patients with advanced solid tumors
Κύριοι συγγραφείς: | Ghazaly, E, Woodcock, V, Spilipoulou, P, Spiers, L, Moschandreas, J, Griffiths, L, Gnanaranjan, C, Harrison, D, Evans, T, Blagden, S |
---|---|
Μορφή: | Conference item |
Έκδοση: |
Oxford University Press
2017
|
Παρόμοια τεκμήρια
-
A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301)
ανά: Pavlina Spiliopoulou, κ.ά.
Έκδοση: (2024-04-01) -
3373 Modulation of Hedgehog Signaling Alters Immune Infiltration in Pancreatic Cancer
ανά: Nina Steele, κ.ά.
Έκδοση: (2019-03-01) -
Pharmacodynamic Parameters of Pharmacokinetic/Pharmacodynamic (PK/PD) Integration Models
ανά: Longfei Zhang, κ.ά.
Έκδοση: (2022-03-01) -
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
ανά: Blagden, SP, κ.ά.
Έκδοση: (2018) -
Pharmacodynamics, chiral pharmacokinetics and PK–PD modelling of ketoprofen in the goat
ανά: Abdul Kadir, Arifah, κ.ά.
Έκδοση: (2003)